## Elamipretide

®

MedChemExpress

Cat. No.:	HY-P0125	
CAS No.:	736992-21-5	NH <sub>2</sub>
Molecular Formula:	C <sub>32</sub> H <sub>49</sub> N <sub>9</sub> O <sub>5</sub>	
Molecular Weight:	639.79	
Sequence:	{d-Arg}-{Dmt}-Lys-Phe-NH2	
Sequence Shortening:	{d-Arg}-{Dmt}-KF-NH2	NH Ö
Target:	Mitochondrial Metabolism	ОН
Pathway:	Metabolic Enzyme/Protease	
Storage:	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 29 mg/mL (45.33 mM)

\* "≥" means soluble, but saturation unknown.

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.5630 mL	7.8151 mL	15.6301 mL
	5 mM	0.3126 mL	1.5630 mL	3.1260 mL
	10 mM	0.1563 mL	0.7815 mL	1.5630 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIV	
Biological Activ	
Description	Elamipretide (MTP-131) is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	Cardiolipin peroxidase <sup>[1]</sup>
In Vivo	Elamipretide (5 mg/kg, i.p., once daily for 3 days) exhibits neuroprotective effects, protects the hippocampus from mitochondrial dysfunction, and attenuates the oxidative stress and inflammatory response in Lipopolysaccharide (HY-D1056)-induced cognitive impairment in C57BL/6 mice model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LPS-induced cognitive impairment in C57BL/6 mice model <sup>[1]</sup>
Dosage:	5 mg/kg
Administration:	i.p., once daily for 3 days
Result:	Maintained the mitochondrial function, ROS and MDA levels, and SOD activity. Inhibited neural cell apoptosis in hippocampus, enhanced the hippocampal BDNF pathway and synaptic structural complexity.

## **CUSTOMER VALIDATION**

- Sci Adv. 2022 Apr 8;8(14):eabl4370.
- Cell Commun Signal. 2024 Jan 10;22(1):26.
- JCI Insight. 2021 Dec 7;e152102.
- Biomed Pharmacother. 2024 Jan 9:171:116110.
- Hum Mol Genet. 2019 Apr 1;28(7):1100-1116.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Zhao W, et al., Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019 Nov 20;16(1):230.

[2]. Sabbah HN,et al., Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA